Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-134 effects on Ketamine-induced BOLD signals
NCT03141658Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Jun 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of TS-134 in schizophrenia (3 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: BOLD fMRI signals in pre-specified ROIs at Day 6. Started Jun 2017; status: completed.
02
Drugs
TS-134
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03141658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03141658.